Nationally recognized as America’s Top Cardiologist. Midtown NYC heart doctor Michael Ghalchi is a contributor to a multiple, industry best rated cardiology journals including “The Journal of Invasive Cardiology”. He is listed on the American Heart Association board of advisors.
As a NYC’s top cardiologist he brings a wealth of experience and skill to every patient. You’ll find top rated, expert cardiologists and physicians, the most up-to-date, best equipped facilities and a relaxing atmosphere at Manhattan Cardiovascular Associated in Midtown, NYC.
InvasiveCardiology.comJournal of Invasive Cardiology: Dr. Michael Ghalchi New York cardiologist identifies, reviews, and discusses a previously under-recognized relationship in the fields of cardiology and oncology in the Journal of Invasive Cardiology. Read more >>
onlinejase.comEchocardiography: Cardiologist Dr. Ghalchi diagnoses a rare congenital heart condition by recognizing an unusual finding on a patient’s echocardiogram and reports his findings in the journal Echocardiography.
FoxNews.comFOX News: A new technology is on the horizon. Fox News asks NYC cardiologist Dr. Michael Ghalchi if there could be potential risks.
Is coffee good or bad for your heart? Dr. Michael Ghalchi, a leading NYC cardiologist and founder of Manhattan Cardiovascular Associates, explains. Health risks of coffee don’t amount to hill of beans. Read more >>
Watch What You Eat: The Do’s And Don’ts Of Social Business Dining. CBS News’ Liz Cho sits down with cardiologist Dr. Michael Ghalchi to discuss the results of an important recent study. Read more >>
TheHill.com asks Dr. Ghalchi to predict what the future of healthcare will look like depending on who wins the presidency. Trump and Clinton have similar ObamaCare results. Read more >>
Carrie Sheffield of Salon.com asks Dr. Michael Ghalchi how the candidates faired with regards to healthcare at the last presidential debate.
Very late stent thrombosis and antineoplastic therapy [Case Report]
Ghalchi, Michael; Chengot, Thomas; Marzo, Kevin
Journal of invasive cardiology. 2010 Dec . 22 (12): E216-E219
Percutaneous coronary intervention (PCI) is now a part of the treatment strategy of patients with both unstable syndromes and chronic angina. As our patients age and live longer with coronary artery disease, many having had PCI, they are more likely to develop potentially life-threatening comorbid conditions, including neoplastic disorders. In the United States, for example, an estimated 41% of the population will develop some form of malignancy.1 As such, they become subject to a multitude of interactions between their cardiac and oncologic diseases, and the therapies used to treat each. This is especially the case when patients have had PCI with drug-eluting stents (DES), as a careful balance between thrombosis and bleeding must be maintained, and is particularly vulnerable to the interactions described above. The following cases and accompanying review will highlight potential risks of very late stent thrombosis with acquired prothrombotic states, following coronary intervention with implantation of both 1st and second-generation DES.
Rare flow pattern in a patient with cor triatriatum (Noninvasive Cardiology)
Ghalchi, Michael; Rosenzweig, Barry P; Colvin, Stephen B; Tunick, Paul A; Kronzon, Itzhak
Echocardiography. 2005 Sep . 22 (8): 705-706
Dr. Michael Ghalchi, Cardiologist (Cardiologist NYC, Midtown)
New York, NY 10010
(Between Madison Ave & Park Ave)
New York, NY 10006
(Near the New York Stock Exchange)
☎ (212) 686-0066